Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:
(a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice.):
1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address:
   John G. Delinasios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH,
   IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
DNA Repair 2014

13th Biennial Conference of the DGDR
(German Society for Research on DNA Repair)

8. – 12. September 2014
University Medical Center Mainz

Topics
• All DNA repair pathways (MGMT, BER, NER, MMR, HR, NHEJ)
• Damage tolerance, TLS
• Regulation of repair genes
• Structure and modification of repair proteins
• Modulation of repair processes by pharmacological inhibitors
• DNA damage response
• DNA damage and cell cycle control
• Repair and aging
• Repair and inflammation
• Repair and carcinogenesis
• Cancer therapy

Speakers
K. Borgmann, H. Ulrich
M. Christmann, J. Thomale
C. Reinhardt, S. Emmert
B. Epe, C. Fournier, A. Bürger
B. Kaina, A. Hartwig, G. Fritz
T. Schwerdtle, F. Rödel
B. Schumacher, G. Illiaikis
S. Jentsch, C. Kissler
W. Mansour, H. Pospiech
M. Löbrich, W.P. Roos
A. Ladurner, V. Jendrossek
T. Hofmann, C. Niehrs
H. Puchta, J. Puizina,
Z.Q. Wang and others

Conference Fee
Non-members: 300 €
Members: 220 €
Students: 150 €
Abstract submission deadline and early booking: June 30, 2014
www.dgdr.de

Hot topic lecturers
Vilhelm A. Bohr, Bethesda
Eugenia Dogliotti, Rome
Jan Hoeijmakers, Rotterdam
Mats Ljungman, Ann Arbor
Leon Mullenders, Leiden

Scientific Advisory Committee
A. Bürger
A. Hartwig
J. Thomale
M. Digweed
K. Borgmann
M. Löbrich
H. Ulrich
G. Fritz
B. Epe
T. Schwerdtle
L. Wiesmüller
F. Grosse

Organization and contact:
Bernd Kaina and coworkers
Institute of Toxicology
University Medical Center
D-55131 Mainz
Tel: +49-(0)6131-17-9357
strauch@uni-mainz.de
A Selection of Recent Papers


Crucial and Novel Cancer Drivers in a Mouse Model of Triple-Negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (Worcester, MA; Bethesda, MD; Scranton, PA; New York, NY, USA; Singapore, Singapore)

Cilia Gene Expression Patterns in Cancer. M. SHPAK, M.M. GOLDBERG, M.C. COWPERTHW AITE (Austin TX, USA)

MicroRNA-150 Is Up-regulated in Extranodal Marginal Zone Lymphoma of MALT Type. N. GEBAUER, J. KUBA, A. SENFT, A. SCHILLERT, V. BERNARD, C. THORNS (Lübeck, Germany)


Fucoidan-dependent Increased Membrane Component in HepG2: Effect of Fucoidan Is Not Due to Gene Expression. K. HAYAKAWA, T. NAGAMINE (Tokyo; Gunma, Japan)


A Novel Transmembrane Glycoprotein Cancer Biomarker Present in the X Chromosome. A.P. DELGADO, S. HAMID, P. BRANDAO, R. NARAYANAN (Boca Raton, FL, USA)

Rho Kinase Proteins Regulate Global miRNA Expression in Endothelial Cells. J.M. STILES, V. KURISETTY, D.C. MITCHELL, B.A. BRYAN (El Paso, TX, USA)

Gene Expression Profiling of Circulating Natural Killer Cells in Head and Neck Squamous Cell Carcinoma. A. BOTTCHER, J. OSTWALD, D. KOCZÁN, R. KNECHT, B. KRAMP, S. DOMMERICH (Hamburg; Rostock; Berlin, Germany)


Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.C.S. CHO, J. WANG, Y.G. MAN (Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou, China; Hong Kong, Hong Kong)

Subscription Order Form 2014

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 34 (2014).

Annual subscription rates (2013): Institutional, Euro 1,650.00 print or online; Personal, Euro 780.00 print or online;
Prices include rapid delivery and insurance.
2014 online subscriptions include free online access to vol. 24 (2004) - 33 (2013).
☐ Please send me the following previous volumes (1-33) at 50% discount on the above rates.
☐ Payment is enclosed. ☐ Please invoice.
Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece)
☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: ...........................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
Tel: ........................................................................................................................ e-mail: ..............................................
Fax: ....................................................................................................................... ______________________________
Signature:............................................................................................................... Date:..................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd.,
Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2014 Offers to Authors of ANTICANCER RESEARCH

These offers are open to all authors of articles published in Anticancer Research from 1981-2014 on a basis of priority and availability.
Effective from January to December 2014.

- Included in PubMed, Current Contents and all abstracting and indexing services
- Online with Stanford University HighWire Press
- Open access articles

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece.

Special Subscription Order Form 2014

☐ I am one of the authors of the article published in Anticancer Research Vol........, pp. ........, year .........
☐ Please enter my personal subscription to Anticancer Research 2014 (Volume 34) at the special Author’s rate of Euro 390.00 (print or online).
☐ Please send me previous Volume No(s) ............ at Euro 195.00 (print) per volume.
☐ Please enter my personal combined 2014 subscription to Anticancer Research (Volume 34) and IN VIVO (Volume 28) at Euro 560.00 (print or online).
☐ My payment is enclosed.
☐ Please send me an invoice.

Prices include rapid delivery and insurance. Checks should be made payable to Delinasios G.J. & CO G.P. (Athens, Greece).

Name and address: ...........................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
........................................................................................................................................................................................................
Tel-Fax: ....................................................................................................................... Tel: ...............................................................
E-mail: ...............................................................................................................................................................................................................
Date and signature: ...............................................................................................................................................................................................................

Your link to the essential information on cancer research published in the last 33 years.
- 1981-2013
- 33 volumes
- over 108,100 pages
- over 16,000 original articles
- 769 reviews
- over 73,300 authors
- Conference abstracts
- Special issues
- Book reviews
- Author-Subject Indexes

Included in Pubmed, Current Contents and all abstracting and indexing services
Online with Stanford University HighWire Press
Open access articles
Expression of Chemotaxis- and Angiogenesis-related Factors in Human Monocytes Following Interaction with Colon Cancer Cells Is Suppressed by Low-dose Lipopolysaccharide. T. HONDA, H. INAGAWA, I. YAMAMOTO (Sagamihara, Kanagawa; Kagawa, Japan) .................................................. 4609

Pre-clinical Study of BK-UM, a Novel Inhibitor of HB-EGF, for Ovarian Cancer Therapy. S.O. NAM, F. YOTSUMOTO, K. MIYATA, Y. SUZAKI, H. YAGI, T. ODAWARA, S. MANABE, T. ISHIKAWA, M. KUROKI, E. MEKADA, S. MIYAMOTO (Fukuoka; Osaka; Kagawa, Japan) ........................................ 4615

Radiosensitivity Uncertainty Evaluation for the In Vitro Biophysical Modeling of EMT6 Cells. M. OITA, Y. UTO, M. TOMINAGA, M. SASAKI, Y. HARA, T. KISHI, H. HORDI (Okayama; Tokushima, Japan) ... 4621

Molecular Analysis of Streptococcus anginosus-derived SagA Peptides. Y. KAWAGUCHI, A. TABATA, H. NAGAMUNE, K. OHKURA (Chiba; Tokushima, Tokushima; Suzuka, Mie, Japan)................................. 4627

Benefit of Lateral Lymph Node Dissection for Rectal Cancer: Long-term Analysis of 944 Cases Undergoing Surgery at a Single Center (1975-2004). T. KINUGASA, Y. AKAGI, K. SHIROUZU (Fukuoka, Japan) ... 4633
An NDT Study of a Boron Tracedrug UTX-51 for Glycated BSA as an AGE Model. R. TADA, Y. UTO, S.-I. MASUNAGA, Y. KINASHI, K. ONO, H. HORIZ (Tokushima; Osaka, Japan) ................................................................. 4503

An Epithelial Cell Adhesion Molecule- and CD3-Bispecific Antibody Plus Activated T-Cells Can Eradicate Chemoresistant Cancer Stem-like Pancreatic Carcinoma Cells In Vitro. M. UMEBAYASHI, A. KIYOTA, N. KOYA, H. TANAKA, H. ONISHI, M. KATANO, T. MORISAKI (Fukuoka, Japan) ................................................................. 4509

Investigation on the Reaction Conditions of Staphylococcus aureus Sortase A for Creating Surface-modified Liposomes as a Drug-delivery System Tool. A. TABATA, N. ANYOJI, Y. OHKUBO, T. TOMOYASU, H. NAGAMUNE (Tokushima, Japan) ................................................................. 4521

NKG2D-directed Cytokine-activated Killer Lymphocyte Therapy Combined with Gemcitabine for Patients with Chemoresistant Metastatic Solid Tumors. T. MORISAKI, T. HIRANO, N. KOYA, A. KIYOTA, H. TANAKA, M. UMEBAYASHI, H. ONISHI, M. KATANO (Fukuoka, Japan) ................................................................. 4529

Multicolor Analysis of Cell Surface Marker of Human Leukemia Cell Lines Using Flow Cytometry. T. INOUE, A. SWAIN, Y. NAKANISHI, D. SUGIYAMA (Fukuoka, Japan) ................................................................. 4539

Resveratrol Induces Luminal Apoptosis of Human Colorectal Cancer HCT116 Cells in Three-dimensional Culture. T. TSUNODA, S. ISHIKURA, K. DOI, H. MATSUZAKI, Y. IWAHARA, S. SHIRASAWA (Fukuoka, Japan) ................................................................. 4551

A Neutron Dynamic Therapy with a Boron Tracedrug UTX-51 Using a Compact Neutron Generator. H. HORIZ, R. TADA, Y. UTO, E. NAKATA, T. MORII, K. MASUDA (Tokushima; Uji, Kyoto, Japan) ................................................................. 4557

Dok2 Likely Down-regulates Klf1 in Mouse Erythroleukemia Cells. Y. TANAKA, K. KULKEAW, T. INOUE, K.S. TAN, Y. NAKANISHI, S. SHIRASAWA, D. SUGIYAMA (Fukuoka, Japan) ................................................................. 4561

Minichromosome Maintenance Protein 7 Is A Risk Factor for Recurrence in Patients with Dukes C Colorectal Cancer. Y. ISHIBASHI, T. KINUGASA, Y. AKAGI, T. OHCHI, Y. GOTANDA, N. TANAKA, S. FUJINO, K. YUGE, S. KIBE, N. YOSHIDA, T. MIZOBE, Y. OKA, T. YOSHIDA, K. SHIROUZU (Fukuoka, Japan) ................................................................. 4569

A Novel Assay System for Macrophage-activating Factor Activity Using a Human U937 Cell Line. M. ISHIKAWA, T. INOUE, T. INUI, D. KUCHIIE, K. KURO, Y. UTO, T. NISHIKATA (Kobe; Tokushima; Osaka, Japan) ................................................................. 4577

Evaluation of the Sonosensitizing Activities of 5-Aminolevulinic Acid and Sn(IV) Chlorin e6 in Tumor-bearing Chick Embryos. Y. UTO, D. TAMATANI, Y. MIZUKI, Y. ENDO, I. NAKANISHI, K. OHKUBO, S. FUKUZUMI, M. ISHIIZUKA, T. TANAKA, D. KUCHIIE, K. KUBO, T. INUI, H. HORIZ (Tokushima; Kanazawa; Chiba; Osaka; Tokyo; Kobe, Japan) ................................................................. 4583


Prospective Evaluation of Safety of Immune-cell Therapy for Patients with Various Types of Advanced Cancer. T. KAMIGAKI, E. MATSUDA, S. OKADA, K. NAITOH, T. KONDO, H. IBE, R. MAEKAWA, S. GOTO (Tokyo, Japan) ................................................................. 4601

Contents continued on the preceding page
Zoledronic Acid Improves Clinical Outcomes in Patients with Bone Metastatic Hormone-naïve Prostate Cancer in a Multicenter Clinical Trial. T. OKEGAWA, M. HIGAKI, T. MATSUMOTO, H. KASE, A. MURATA, K. NODA, H. NODA, H. ASAO, M. OSHI, J. TOMOISHI, H. UCHIDA, E. HIGASHIHARA, K. NUTAHARA, BONE METASTASIS PROSTATE CANCER GROUP (Mitaka; Tachikawa; Hachioji; Nishitokyo; Suginami; Nishitokyo; Akiruno; Fuchu; Ome; Tokyo, Japan) .............................................. 4415

Surgical Outcomes of Anatomical Resection for Solitary Recurrent Hepatocellular Carcinoma. Y.-I. YAMASHITA, D. IMAI, Y. BEKKI, K. TAKEISHI, E. TSUJITA, T. IKEGAMI, T. NISHIZUMI, T. IKEDA, K. SHIRABE, T. ISHIDA, Y. YAMASHITA, H. NODA, H. ASAOKA, M. OSHI, J. TOMOISHI, H. UCHIDA, E. HIGASHIHARA, K. NUTAHARA, BONE METASTASIS PROSTATE CANCER GROUP (Mitaka; Tachikawa; Hachioji; Nishitokyo; Suginami; Nishitokyo; Akiruno; Fuchu; Ome; Tokyo, Japan) .............................................. 4421

Hypothyroidism After Radiotherapy for Primary Thyroid Lymphoma. N. ISHIBASHI, T. MAEBAYASHI, T. AIWA, M. SAKAGUCHI, O. ABE, T. SAITO, J. KAWAMORI, Y. TANAKA (Tokyo; Kanagawa, Japan) .............................................................. 4427

Longitudinal Analysis of Late Vaginal Mucosal Reactions After High-dose-rate Brachytherapy in Patients with Gynecological Cancer. K. YOSHIDA, H. YAMAZAKI, S. NAKAMURA, K. MASUI, T. KOTSUMA, A. AKIYAMA, E. TANAKA, Y. NARUMI, Y. YAMASHITA, H. NODA, H. ASAOKA, M. OSHI, J. TOMOISHI, H. UCHIDA, E. HIGASHIHARA, K. NUTAHARA, BONE METASTASIS PROSTATE CANCER GROUP (Mitaka; Tachikawa; Hachioji; Nishitokyo; Suginami; Nishitokyo; Akiruno; Fuchu; Ome; Tokyo, Japan) .............................................. 4433

Detection of Thyroid Cancer by an FDG-PET Cancer Screening Program: A Japanese Nationwide Survey. R. MINAMIMOTO, M. SENDA, S. JINNOUCHI, T. TERAUCHI, T. YOSHIDA, T. INOUE (Tokyo; Kobe; Kagoshima; Kurume; Yokohama, Japan) ............................................................................................ 4439

The Role of Interim 18F-FDG PET/CT in Predicting Early Response to Neoadjuvant Chemotherapy in Breast Cancer. K. PAHK, S. RHEE, J. CHO, M. SEO, S. LEE, T. PARK, S. PARK, E. LEE, K.H. PARK, C. KIM, J.S. EO, S. KIM, J.G. CHOE (Seoul; Ansan, South Korea) .......................................................... 4447

Clinical Significance of Urokinase-type Plasminogen Activator (uPA) and its Type-1 Inhibitor (PAI-1) for Metastatic Sentinel Lymph Node Involvement in Breast Cancer. W. HARMS, W. MALTER, S. KRÄMER, U. DREBBER, A. DRZEZGA, M. SCHMIDT (Cologne, Germany) ................................................................. 4457

Clinicopathological Characteristics and Prognosis of Patients According To Recurrence Time After Radical Nephrectomy for Localized Renal Cell Carcinoma: A Multicenter Study of Anatolian Society of Medical Oncology (ASMO). O. BOZKURT, M. İNANC, I. HACIBEKİROĞLU, O. ESBAH, M. SEKER, A. ULAS, K. AYDIN, M. UYSAL, M. KÜÇÜKÖNER, D. UNCU, A. CİLTAS, O.Ü. ÜNAL, A. DURNALI, U. DEMİRCİ, V. BERK, O. TONYALI, B. OKSÜZOGLU, H. KARACA, M. OZKAN (Kayseri; Trakya; Ankara; Sivas; Istanbul; Afyon; Diyabakir; İzmir; Elazığ, Turkey) .............................................................. 4463

Prediction of Lymph Node Metastasis in Patients with Submucosa-Invading Early Gastric Cancer. A. SHIDA, S. FUJIOKA, M. KAWAMURA, N. TAKAHASHI, Y. ISHIBASHI, K. NAKADA, N. MITSUMORI, N. OMURA, K. YANAGA (Tokyo, Japan) ........................................................................ 4471

Errata ............................................................................................................................................ 4475

Proceedings of the 17th Annual Meeting of the Society of Biotherapeutic Approaches. Special Issue Edited by M. Kuroki and G.-I. Soma ........................................................................................................ 4477

Preface ........................................................................................................................................... 4479

Review: Novel Treatment Strategies for Cancer and Their Tumor-targeting Approaches Using Antibodies Against Tumor-associated Antigens. M. KUROKI, N. SHIRASU (Fukuoka, Japan) ................................................................. 4481

Review: The Roles of ZFAT in Thymocyte Differentiation and Homeostasis of Peripheral Naive T-Cells. K. DOI, S. ISHIKURA, S. SHIRASAWA (Fukuoka, Japan) ........................................................................ 4489

Review: Usefulness of Oral Administration of Lipopolysaccharide for Disease Prevention Through the Induction of Priming in Macrophages. H. INAGAWA, C. KOHCHI, G.-I. SOMA (Takamatsu, Kagawa; Niigata, Niigata, Japan) ........................................................................ 4497
Surgical Treatment of Colorectal Cancer Pulmonary Metastases: 12-year Results. J. VODICKA, V. SPIDLEN, V. TRESKA, J. FICHTL, V. SIMANEK, J. SAFRANEK, S. VEJVODOVA, P. MUKENSNABL, O. TOPOLCAN (Pilsen, Czech Republic) ................................................................. 4239


Seminoma Patients Treated at a Minor Oncological Department During 1986-2010: Treatment and Outcome. H.S. HAUGNES, Ø. SOLHAUG, J. STENBERG, L.V. HJELLE, R.M. BREMNES (Tromsø; Leknes; Stokmarknes, Norway) ............................................................................................................................ 4253

Feasibility of Simultaneous Integrated Boost IMRT (SIB-IMRT) for Castration-Resistant Prostate Cancer. T. HAKARIYA, S. OBATA, T. IGAWA, H. SAKAI (Nagasaki, Japan) ..................................................................................................................... 4261

Macroscopic Type Is a Prognostic Factor for Recurrence-free Survival After Resection of Gastric GIST. H. MIYAMOTO, C. KUNISAKI, Y. OTSUKA, M. TAKAHASHI, R. TAKAGAWA, K. MISUTA, K. KAMEDA, H. MAKINO, G. MATSUDA, N. YAMAGUCHI, N. KAMIYA, T. MURAKAMI, S. MORITA, H. AKIYAMA, I. ENDO (Yokohama; Tokyo; Fujisawa; Yokosuka; Ito, Japan) ........................................ 4267


Elderly Woman with Triple-negative Metastatic Breast Cancer Successfully Treated with Metronomic Capecitabine. F. DE IULIIS, G. SALERNO, L. TAGLIERI, R. VICINANZA, R. LANZA, S. SCARPA (Rome, Italy) ..................................................................................................................................................... 4287

Postoperative Functional Evaluation of Gastric Tube After Laparoscopic Proximal Gastrectomy for Gastric Cancer. E. MOCHIKI, M. FUKUCHI, K. OGATA, T. OHNO, H. ISHIDA, H. KUWANO (Saitama; Gunma, Japan) ........................................................................................................ 4293

Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement. S. PARK, B. HAN, K. KIM, S.J. KIM, J.H. JANG, W.S. KIM, C.W. JUNG (Seoul; Anyang, South Korea) ........................................................................................................................................ 4299

Living Donor Liver Transplantation Followed by Total Gastrectomy – A Two-stage Planed Operative Strategy for Early Gastric Cancer Concomitant with Decompensated Liver Cirrhosis. S. NISHIMURA, H. SAEKI, T. IYEGAMI, K. ANDO, Y.-I. YAMASHITA, E. OKI, T. YOSHIZUMI, M. MORITA, K. SHIRABE, Y. MAEHARA (Fukuoka, Japan) .................................................................................................................. 4307


No Infectious Hepatic Complications Following Radioembolization with 90Y Microspheres in Patients with Biliodigestive Anastomosis. D. GEISEL, M.-J. POWERSKI, D. SCHNAPAUFF, F. COLLETTINI, R. THIEL, T. DENECKE, G. WIENERS, B. GEBAUER (Berlin, Germany) .................................................................................................................. 4315

Contents continued on the preceding page


α-Phellandrene Alters Expression of Genes Associated with DNA Damage, Cell Cycle, and Apoptosis in Murine Leukemia WEHI-3 Cells. J.-J. LIN, C.-C. YU, K.-W. LU, S.-J. CHANG, F.-S. YU, C.-L. LIAO, J.-G. LIN, J.-G. CHUNG (Taichung, Taiwan, ROC) ......................................................... 4161

Clinical Studies

Claudins as Prognostic Factors for Renal Cell Cancer. J. VIRMAN, Y. SOINI, P. KUJALA, T. LUUKKAALA, T. SALMINEN, K. SUNELA, P.-L. KELLOKUMPУ-LEHTINEN (Tampere; Kuopio, Finland) ............................................................. 4181


Predictive Biomarkers for the Outcome of Vaccination of Five Therapeutic Epitope Peptides for Colorectal Cancer. S. HAZAMA, H. TAKEUCHI, R. TSUNEKAWA, M. HIRAI, N. SUZUKI, N. IIZUKA, Y. INOUE, K. SAKAMOTO, M. NAKAO, Y. SHINDO, S. KANEKIYO, Y. TAKUMITSU, K. YOSHIMURA, N. MAEDA, K. MAEDA, Y. MAEDA, H. MATSUI, S. YOSHINO, Y. NAKAMURA, Y. FUJIYAMA, Y. HAMAMOTO, M. OKAMOTO, T. FUJITA, Y. KAWAKAMI, M. OKA (Ube, Yamaguchi; Tokyo, Japan; Chicago, IL, USA) ......................................................... 4201

Significance of Accurate Human Epidermal Growth Factor Receptor-2 (HER2) Evaluation as a New Biomarker in Gastric Cancer. Y. KIMURA, E. OKI, A. YOSHIDA, S. AISHIMA, Y. ZAITSU, H. OHTSU, K. ANDO, S. IDA, H. SAEKI, M. MORITA, T. KUSUMOTO, Y. ODA, Y. MAEHARA (Fukuoka, Japan) ......................................................... 4207


Expression of Statm1 in Gastric Adenocarcinoma. B.-E. BATSAIKHAN, K. YOSHIKAWA, N. KURITA, T. IWATA, C. TAKASU, H. KASHIHARA, M. SHIMADA (Tokushima, Japan) ......................................................... 4217

Prognostic Nutritional Index is Associated with Survival After Total Gastrectomy for Patients with Gastric Cancer. M. ISHIKAWA, Y. OYAMA, A. ABE, K. TAGO, G. TANAKA, K. KUBOTA (Mibu, Tochigi, Japan) ......................................................... 4223

SOX18 Expression Predicts Response to Platinum-based Chemotherapy in Ovarian Cancer. B. PULA, C. KOBIERZYCKI, D. SOLINSKI, M. OLBROMSKI, E. NOWAK-MARKWITZ, M. SPACZYNSKI, W. KEDZIA, M. ZABEL, P. DZIEGIEL (Wroclaw; Poznan, Poland) .................. 4029

Dehydroepiandrosterone Inhibits Proliferation and Suppresses Migration of Human Cervical Cancer Cell Lines. Y.N. ORTEGA-CALDERÓN, R. LÓPEZ-MARURE (México City, México) .................. 4039

A Tertiary Sulfonium Compound, Dimethylsulfoniopropionate in Green Sea Algae, Completely Suppresses Crucial Ehrlich Ascites Carcinoma in Mice. K. NAKAJIMA, S. TSUIJWAKI, Y. NAKAJIMA (Takarazuka, Hyogo; Okayama, Japan) .................. 4045


Expression of Nogo Isoforms and Nogo-B Receptor (NgBR) in Non-small Cell Lung Carcinomas. B. PULA, B. WERYNSKA, M. OLBROMSKI, B. MUSZCZYNSKA-BERNHARD, M. CHABOWSKI, D. JANCZAK, M. ZABEL, M. PODHORSKA-OKOLOW, P. DZIEGIEL (Wroclaw; Poznan, Poland) .......... 4059

Silencing of Phosphoinositide-specific Phospholipase C ε Remodulates the Expression of the Phosphoinositide Signal Transduction Pathway in Human Osteosarcoma Cell Lines. V.R. LO VASCO, M. LEOPIZZI, D. STOPPOLONI, C. DELLA ROCCA (Rome, Italy) .................. 4069

Evaluating the Cytotoxic Effects of Novel Quinone Compounds. M. SAIBU, S. SAGAR, I. GREEN, F. AMEER, M. MEYER (Bellville, South Africa) .................. 4077


High Oxygen Partial Pressure Increases Photodynamic Effect on HeLa Cell Lines in the Presence of Chloraluminium Phtalocyanine. R. BAJGAR, H. KOLAROVA, L. BOLEK, S. BINDER, K. PIZOVA, A. HANAKOVA (Olomouc; Plzen, Czech Republic) .................. 4095

Targeting the Wnt/Beta-Catenin Pathway in Renal Cell Carcinoma. S.A. VON SCHULZ-HAUSMANN, L.C. SCHMEEL, F.C. SCHMEEL, I.G.H. SCHMIDT-WOLF (Bonn, Germany) .................. 4101

Evaluation of the Contribution of Methylenetetrahydrofolate Reductase Genotypes to Taiwan Breast Cancer. C.-Y. SUZUKI, S. M. MATSUO, H. SAKAGAMI, Y. OKADA, Y. SHIRATAKI (Saitama; Tokyo, Japan) .................. 4117

Serum Vimentin Methylation as a Potential Marker for Colorectal Cancer. A. SHIRAHATA, K. HIBI (Yokohama Japan) .................. 4121


Semi-synthesis of Nitrogen Derivatives of Oleanolic Acid and Effect on Breast Carcinoma MCF-7 Cells. O.O. OYEDEJI, F.O. SHODE, A.O. OYEDEJI, S.P. SONCGA, E.T. GWEBU, G.M. HILL, W.N. SETZER (Alice; KwaDlangezwa; Mthatha, South Africa; Elizabeth City, NC; Huntsville, AL, USA) .................. 4135

Contents continued on the preceding page
Tumor Regression by CD4 T-Cells Primed with Dendritic/Tumor Fusion Cell Vaccines. S. KOIDO, Y. ENOMOTO, V. APOSTOLOPOULOS, J. GONG (Chiba; Tokyo, Japan; Melbourne, VIC, Australia; Boston, MA, USA) ........................................................................................................................................ 3917

Optimal Production of a Fusion Protein Consisting of a Single-chain Variable Fragment Antibody Against a Tumor-associated Antigen and Interleukin-2 in Fed-batch Culture of Pichia pastoris. S. ANULEEJUN, T. PALAGA, Y. KATAKURA, MOTOMU KUROKI, MASAHIDE KUROKI, S.C. NAPATHORN (Bangkok, Thailand; Suita; Fukuoka, Japan) ................................................................................................................ 3925

High Expression of Fusion Proteins Consisting of a Single-chain Variable Fragment Antibody Against a Tumor-associated Antigen and Interleukin-2 in Escherichia coli. S.C. NAPATHORN, MOTOMU KUROKI, MASAHIDE KUROKI (Bangkok, Thailand; Fukuoka, Japan) .......................................................................................................................... 3937

Random Migration Contributes to Cytotoxicity of Activated CD8+ T-Lymphocytes But Not NK cells. H. ONISHI, A. KIYOTA, N. KOYA, H. TANAKA, M. UMEBAYASHI, M. KATANO, T. MORISAKI (Fukuoka, Japan) ............................................................................................................................ 3947

Prognostic MicroRNA Expression Signature from Examination of Colorectal Primary and Metastatic Tumors. C. ELLERMEIER, S. VANG, K. CLEVELAND, W. DURAND, M.B. RESNICK, A.S. BRODSKY (Providence, RI, USA) ............................................................................................................................ 3957

Nuclear Expression of Phosphorylated Focal Adhesion Kinase Is Associated with Poor Prognosis in Human Colorectal Cancer. A. ALBASRI, W. FADHIL, J.H. SCHOLEFIELD, L.G. DURRANT, M. ILYAS (Nottingham, UK; Medina, Saudi Arabia) ........................................................................................................................................ 3969

Potentiation of Natural Killer Cell Activity with Myricetin. C. LINDQVIST, M. BOBROWSKA-HÄGERSTRAND, L. MRÓWCZYŃSKA, C. ENGBLOM, H. HÄGERSTRAND (Turku, Finland; Poznań, Poland) ........................................................................................................................................ 3975


Extracellular Matrix of Galectin-1-exposed Dermal and Tumor-associated Fibroblasts Favors Growth of Human Umbilical Vein Endothelial Cells In Vitro: A Short Report. V. PERŽELOVÁ, L. VARINSKÁ, B. DVORÁNKOVÁ, P. SZABO, P. SPURNÝ, J. VALACH, J. MOJZIŠ, S. ANDRÉ, H.-J. GABIUS, K. SMETANA JR., P. GÁL (Košice; Bratislava, Slovak Republic; Prague, Czech Republic; Munich, Germany) ........................................................................................................................................ 3991

Expression of Somatostatin Type-2 and -4 Receptor and Correlation with Histological Type in Breast Cancer. A. FRATI, R. ROUZIER, B. LESIEUR, G. WERKOFF, M. ANTOINE, A. RODENAS, E. DARAI, E. CHEREAU (Paris; Marseille, France) ........................................................................................................................................ 3997


Novel Piperazinediones as Antitumor Agents. C.-L. WANG, O. LEE, G. HSIAO, J.-F. LIAN, Y.-W. CHENG (Taiwan; Hsinchu; Taoyuan, Taiwan, ROC) ........................................................................................................................................ 4013

Activation of the Leukemia Plasmacytoid Dendritic Cell Line PMDC05 by Toho-1, a Novel IDO Inhibitor. A. YAMAHIRA, M. NARITA, M. IWABUCHI, T. UCHIYAMA, S. IWAYA, R. OHIWA, Y. NISHIZAWA, T. SUZUKI, Y. YOKOYAMA, S. HASHIMOTO, J. TAKIZAWA, H. SONE, M. TAKAHASHI (Niigata; Chiba; Nagaoka, Japan) ........................................................................................................................................ 4021